Spectacle Lenses For Myopia
Our clinic, Specs & Spines Optometry, has been active in Myopia Management since our opening in 2016 and actively fitting spectacle lens designs available in Canada.
The first specialty spectacle lens design called HOYA MIYOSMART was released in 2021, during the height of the pandemic.
We have been able to help patients of all ages and geographical areas (Greater Toronto Area, Etobicoke, Brampton, Mississauga, Oakville, Burlington, Concord, Durham region) to find solutions for the myopia epidemic. Unfortunately, the spectacle lenses such as Miyosmart and Stellest are not yet available in the United States.
While there are new optical labs that are producing lenses that are labelled as “myopia control” designs, patients should have buyer beware that only specific lens designs have been backed by randomized control trials and peer-reviewed data from research clinics around the world.
Our clinic has access to the lens designs that set the standard of care for treatment to slow myopia progression and use diagnostic tests to measure axial length to monitor your child’s progress.
Essilor Stellest - The Next Generation of Myopia Spectacle Lens
Stellest's technical superiority
Essilor® Stellest® lens is one of the newest generation of myopia controlling spectacle lenses, appearing to have efficacy to slow myopia progression in children at least as good as the current 'best' interventions of orthokeratology, dual-focus soft contact lenses and 0.05% atropine.
Clinically proven
A state-of-the-art 2-year clinical trial demonstrated strong evidence for the efficacy of Stellest™ lenses. Both one-year and two-year randomized control trial data have been published. In children who wore Essilor® Stellest® lenses for at least 12 hours per day, 7 days per week, their final axial length and myopia was respectively 0.41mm and 0.99D less than children who wore single vision spectacles. The Essilor® Stellest® lens is designed with Highly Aspherical Lenslet Target ("H.A.L.T.") Technology.
Essilor® Stellest™ lenses slow down myopia progression by 67% on average1, compared to single vision lenses, when worn 12 hours a day.
The eye growth of 9 out of 10 children wearing Essilor® Stellest™ lenses was similar to or slower than non-myopic children
2 out of 3 children who wore Stellest™ lenses had a stable need for vision correction after the first year
Miyosmart - The Gold Standard Myopia Control Spectacle Lens Design
MiyoSmart is a spectacle lens design that uses D.I.M.S. technology for myopia control which was developed by Hoya in partnership with The Hong Kong Polytechnic University. In 2018, the MiyoSmart lens with D.I.M.S. technology was awarded the prestigious Grand Prize, Grand Award and Gold Medal at the 46th International Exhibition of Inventions of Geneva, Switzerland.
What is DIMS technology?
D.I.M.S stands for Defocus Incorporated Multiple Segments. It is the basis of Hoya’s myopia control lenses, known as MiyoSmart. The lens is comprised of a central optical zone for correcting refractive error and multiple defocus segments evenly surrounding the central zone (extending to the midperiphery) of the lens to control myopia progression. This provides clear vision and myopic defocus simultaneously at all viewing distances.
How does it work to slow down myopia?
The lens makes use of the natural homeostatic mechanism known as “emmetropisation”, whereby the eyeball adapts and shapes to receive focused images as it does for normal vision. Creating a myopic defocus (bringing rays in front of the retina) as with MiyoSmart lenses, prevents eyeball (axial length) elongation which is linked to myopia progression.
What are the main benefits of MiyoSmart?
MiyoSmart is a safe and non-invasive option for slowing myopia progression. The wearer receives correction of his/her refractive error while his/her myopic progression is slowed down. MiyoSmart also allows the wearer to move around with ease, as the lenses are impact-resistant. The lens is aesthetically pleasing with its smooth surface and near-identical appearance to single vision lenses. A clinical study concluded that MiyoSmart with DIMS Technology had myopia progression reduced by an average of 60%.
Have the effects of MiyoSmart been clinically proven?
Yes. Beyond correcting myopic refractive error, a two-year clinical trial started in 2014 involving 160 children aged 8-13, showed that MiyoSmart with D.I.M.S. (Defocus Incorporated Multiple Segments) technology works to curb myopic progression by up to 59%
The results of the trial also showed that the children using the MiyoSmart lens had less axial elongation by up to 60% as compared to those wearing single vision lenses.
What is the recommended adaptation period?
We recommend a 1 to 2 weeks adaptation period where we suggest constant wear and to avoid sports. MiyoSmart is considered to be very easy to get used to, compared to a new pair of single vision lenses.
What is the recommended age for MiyoSmart?
In general, MiyoSmart lenses are suitable for patients aged 6-18. It can be prescribed when the first sign of myopia appears and for as long as there are signs of progression. The final determination is made by the Eye Care Professional.
https://www.hoyavision.com/en-ca/vision-products/miyosmartvr25/
ZEISS MyoCare innovation
New lens designs to deliver simultaneous competing defocus.
A Myopia Management lens design aimed at slowing the progression of myopia in children is based on two key aspects.
ZEISS C.A.R.E. technology (Cylindrical Annular Refractive Elements)
Alternating defocus and correction zones in a ring-like pattern on the front surface, expanding toward the periphery of the lens. These microstructures deliver a “stop signal” to slow the progression of axial elongation.6
ZEISS ClearFocus design
Aimed at removing the growth signal, the optimized back surface minimizes hyperopic defocus in the periphery of the lens. Both the refractive correction and the patient’s intended myopic defocus are maintained for all gaze directions. This technology supports the effectivity and wearability of ZEISS MyoCare lenses.
